The BOLERO-1 phase-III randomized study similarly showed a prolongation of progression-free survival by combined treatment of Trastuzumab with Paclitaxel and Everolimus in patients with HER2+ HR− advanced breast cancer, although this did not reach protocol-specified significance56. Here, ERBB2 is linked to breast carcinoma.